PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community remains optimistic for a cure or disease modifying treatment for Alzheimer’s, with particular faith in the amyloid hypothesis. Industry, advocacy groups, academia, and many other stakeholders in clinical development continue to embrace new technologies and data science with the hope that one day these will contribute toward bringing treatments to the right patients at the right stage of the disease.
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
Clinical Research for Dummies
PRA has sponsored Clinical Research for Dummies to help to educate and encourage clinical trial participation. Trial participation starts with…
PRA Health Sciences Investor Relations